Figure 5.

Inhibition of NF-κB/IKKβ signaling by the IKKβ inhibitor, CompA sensitizes cisplatin resistant cells to cisplatin. A. Cells were treated with different doses of CompA for 2 hours, lysed and analyzed by western blots. B. Cells were treated with CompA alone, cisplatin alone, or CompA and cisplatin together for 48 hours and Caspase 3/7 activity was evaluated (*, P < 0.05; **, P < 0.01). C. Cells were treated with CompA alone, cisplatin alone, or CompA and cisplatin together for 48 hours and cleaved caspase 3 and GAPDH were determined. The experiments were repeated three times. D. Cells were pre-treated with CompA, cisplatin, or CompA plus cisplatin and colony formation was observed and the numbers of colony were counted. The results are representative of three independent experiments.